Scorpius BioManufacturing, a Texas-based biologics contract research and contract development & manufacturing organisation (CDMO), has announced the appointment of Gary Welch as Interim President.
With a career spanning more than 30 years in biopharmaceuticals at large manufacturers like AbbVie and biotech innovators like Agensys and CytomX, Gary will lead Scorpius through its next phase of growth, focused on serving clients working on mammalian and microbial biologics and new modalities.
Jeff Wolf, Executive Chairman of Scorpius, said: “With extensive experience in process engineering, manufacturing, analytical development, CMC, and site operations, Gary brings a wealth of knowledge to the team. His leadership will help Scorpius to continue on our path to becoming a world-class CDMO.”
We have an extremely experienced team in terms of operating world-class facilities and successfully commercialising biological drugs
In April, Scorpius will open new microbial capacity to supplement the mammalian suites at its state-of-the-art facility in San Antonio, Texas, which is focused on clinical-scale production.
Scorpius is committed to building US-based biomanufacturing capacity, with plans to construct a commercial-scale facility in Manhattan, Kansas. This will enable innovators in both microbial and mammalian modalities to start their projects quickly using the available capacity at San Antonio and remain with Scorpius throughout the entire product lifecycle as the company continually scales to serve the needs of its customers.
“I am honoured to lead Scorpius as this exciting growth phase continues,” Welch said. “We have an extremely experienced team in terms of operating world-class facilities and successfully commercialising biological drugs. Having been on the contract manufacturing side and the innovator side, like many of my colleagues, I understand customers’ needs and we are creating an environment where their voices are heard, and we deliver for them.”
